header logo image


Page 42«..1020..41424344

Archive for September, 2020

Researchers teamed up to develop a ‘three in one’ HIV treatment and the NIH is throwing in $14.6M – Endpoints News

Thursday, September 3rd, 2020

The NIH is pitching $14.6 million into a three for one HIV research program led by USC and the Fred Hutchinson Cancer Research Center that aims to strike the need for daily medication or even achieve a home run cure.

The five-year grant will back preclinical studies that combine gene editing with technology to improve bone marrow transplants. The potential therapy would engineer a patients own stem cells to fight HIV, and stimulate them to produce new immune cells once reintroduced to the patient.

A home run would be that we completely cure people of HIV, Paula Cannon, a USC professor of molecular microbiology and immunology and co-director of the program, said in a statement. What Id be fine with is the idea that somebody no longer needs to take anti-HIV drugs every day because their immune system is keeping the virus under control, so that it no longer causes health problems and, importantly, they cant transmit it to anybody else.

Hans-Peter Kiem, the Stephanus Family Endowed Chair for Cell and Gene Therapy at Fred Hutch, is the co-director. Harvard University professor David Scadden and Magenta Therapeutics are also collaborating on the project.

The approach was inspired by three patients who appear to have been cured of the virus all of whom received blood stem cell transplants from donors who carried a mutation in the CCR5 gene. One of them, dubbed the Berlin patient, has been off antiretroviral drugs since 2007.

I think of the Berlin patient as proof of principle that replacing the immune system with one thats HIV-resistant by removing CCR5 is a possible way to treat somebody, Cannon said.

The program will study the use of gene editing to remove CCR5 from patients stem cells a process which is already in clinical trial for HIV treatment at City of Hope National Medical Center in Duarte, CA. The stem cells will also be engineered to release antibodies and antibody-like molecules that block HIV.

In addition, the grant will fund a Fred Hutch teams endeavor to adapt CAR-T cell therapy to create stem cells whose progeny target HIV-infected cells.

As for preparing a patient for the transplant,Magenta is working on antibody-drug conjugates to replace mild chemotherapy or radiotherapy typically given before the procedure. And Scadden is researching an injectable gel that could help immune cells repopulate more quickly, avoiding a delay.

HIV infection, which currently affects about 1.2 million Americans, has proved to be exceedingly difficult to cure. In July, Merck and Dewpoint inked a deal that allows the pharma to use the Boston-based biotechs biomolecular condensate technology to develop treatments, and potentially a cure, for the HIV virus. The NIH-funded group is hoping to at least control the virus enough to eliminate the need for daily meds. But at best, theyre also eyeing a long sought-after cure.

This grant funds a team with an overarching goal of developing what our perfect HIV gene therapy would look like, Cannon said. All of these pieces could happen separately, but the fact that the NIH has funded us as a team means that the sum will be so much bigger than the parts.

Original post:
Researchers teamed up to develop a 'three in one' HIV treatment and the NIH is throwing in $14.6M - Endpoints News

Read More...

Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020 -…

Thursday, September 3rd, 2020

New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinsons Disease

Voyager to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentations at the International Parkinson and Movement Disorder Virtual Congress 2020 taking place on September 12-16, 2020. The presentations include new two- and three-year data related to its VY-AADC gene therapy treatment for Parkinsons disease being developed in collaboration with Neurocrine Biosciences:

Additionally, the company plans to participate in the following virtual investor conferences in September:

The webcast sessions may be accessed from the Investors & Media section of Voyagers website at http://www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyagers wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinsons disease, Huntingtons disease, Friedreichs ataxia, and other severe neurological diseases. For more information, please visit http://www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Investor Relations: Paul CoxVP, Investor Relations857-201-3463pcox@vygr.com

Media: Sheryl Seapy W2Opure949-903-4750sseapy@purecommunications.com

Read more here:
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020 -...

Read More...

Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it’s a doozy – Endpoints News

Thursday, September 3rd, 2020

Fouad Namouni, a storied research exec who went from project leader on Opdivo and Yervoy to the top of the oncology research group at Bristol Myers Squibb, is joining the migration to biotech, picking up a new hat as president of R&D at Blueprint Medicines.

Once again, hes headed into a toe-to-toe showdown with a rival pharma organization.

Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprints RET rival to Eli Lillys Retevmo, which got out in front with a May approval. Ironically, Lillys deal to buy into RET with its acquisition of Loxo also brought Josh Bilenker and his crew to the pharma giant, marking a rare career trajectory from a biotech into pharma, which has been bleeding talent for years now.

Unlock this story instantly and join 89,400+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continued here:
Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it's a doozy - Endpoints News

Read More...

Obsidian Therapeutics Appoints Rob Ross, MD, to Board of Directors – PRNewswire

Thursday, September 3rd, 2020

CAMBRIDGE, Mass., Sept. 3, 2020 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross, M.D., to its Board of Directors. Dr. Ross currently serves as the Chief Medical Officer of Surface Oncology.

"Rob brings strong clinical development experience, specifically in oncology, which will be invaluable as we advance towards the clinic," said Paul K. Wotton, Ph.D., Obsidian's Chief Executive Officer. "Rob has successfully advanced multiple programs from IND to pivotal trials, as well as led collaborations with industry and academic partners. His experience in progressing novel and innovative therapies, including cell and gene therapies, from the bench to the bedside will expedite the development of the first cytoDRiVE-based programs into human clinical trials to our ultimate goal of treating cancer patients with controllable living medicines."

Dr. Ross added, "Obsidian addresses a key unmet need in cell and gene therapy through the ability to regulate the biological activity of engineered cells, allowing the creation of highly effective, titratable and targeted immune-oncology therapies. I look forward to contributing to Obsidian's growth and clinical progress."

Dr. Ross serves as the Chief Medical Officer of Surface Oncology and oversees all clinical and regulatory operations and development efforts. He is responsible for advancing Surface Oncology's programs into the clinic. Rob has extensive clinical development experience, most recently at bluebird bio where he led the clinical development of genetically modified cellular therapies in betathalassemia and sickle cell disease. Rob was also the head of oncology at bluebird bio, building a multifaceted oncology program, led by an anti-BCMA chimeric antigen T cell therapy in collaboration with Celgene. Previously, he worked at Genentech and Infinity Pharmaceuticals on both small molecule and antibody programs from Phase I through pivotal trials, and was a faculty member at the Dana Farber Cancer Center, treating patients with genitourinary malignancies. Rob earned his bachelor's degree from Stanford University, his master's degree from Harvard Medical School and his medical degree from Columbia University Vagelos College of Physicians and Surgeons. Rob did his residency in internal medicine at the University of California, San Francisco and his fellowship in hematology/oncology at the combined program at the Dana Farber/Massachusetts General Hospital.

About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE platform provides, for the first time, a technology to develop a new generation of cell and gene therapies in which the level and timing of protein activity are fully controlled in a dose-dependent platform comprises a therapeutic protein of interest fused to a drug-responsive domain (DRD). In the absence of the small molecule drug, the DRD-tagged protein is degraded before it becomes active. In contrast, when the small molecule drug is present, the DRD-tagged protein is stabilized and active, permitting precise control of the timing and level of protein expression. The platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company is headquartered in Cambridge, Mass. For more information, please visit http://www.obsidiantx.com.

Media Contact: Maggie Beller Russo Partners, LLC [emailprotected]646-942-5631

SOURCE Obsidian Therapeutics

Home

Read the rest here:
Obsidian Therapeutics Appoints Rob Ross, MD, to Board of Directors - PRNewswire

Read More...

Dutch Amarna Therapeutics Announces the Appointment of Steen Klysner as Chief Executive Officer – b3c newswire

Thursday, September 3rd, 2020

LEIDEN, the Netherlands, September 03, 2020 / B3C newswire / -- Amarna Therapeutics, a privately held biotechnology company developing the next-generation SV40-based gene delivery vector platform named SVec that promises to transform gene-replacement and immunotherapy across many disease areas, today announced the appointment of Steen Klysner, Ph.D. as its new Chief Executive Officer (CEO) as per September 1. Founder and CEO Ben van Leent will become a member of Amarnas Supervisory Board.

I am very pleased to welcome Steen Klysner as our new CEO. Steen brings an extensive background as a biotech CEO to Swedish ExpreS2ion Biotech Holding AB & the Danish ExpreS2ion Biotechnologies ApS, preceded by an impressive track record in execution and value creation within the biotech industry. His leadership experience makes Steen an ideal candidate to lead Amarna into its next stage of growth and development. said Thomas Eldered, Chairman of Amarnas Supervisory Board. We are extremely grateful for Ben van Leents leadership and contributions to Amarna as both founder and CEO, and we are excited about the opportunity to focus his outstanding expertise as member of our Board.

I am incredibly honored to have been given the opportunity to lead Amarna, said Dr. Klysner. SVec has the potential to enable major medical breakthroughs, so that patients can be actually cured of life-threatening diseases for which, to date, effective treatment have not become available. Together with Amarnas highly qualified and experienced team, Im fully committed to advance the companys groundbreaking technology into the next important clinical development stages.

Steen Klysner comes to Amarna with over 30 years of experience in the life sciences industry. Prior to joining Amarna, Dr. Klysner served as CEO of the Swedish ExpreS2ion Biotech Holding AB in parallel with the Danish ExpreS2ion Biotechnologies ApS. Earlier, he was Senior Vice President (SVP) of preclinical R&D and SVP of Quality of Allergopharma, the Allergy Business Unit of Merck KGaA. He also served as CEO of Nordic Vaccine in Copenhagen, focusing on the development of non-invasive vaccination based on an integrated nanoparticle adjuvant and delivery platform. Prior to that he has also held positions at Pharmexa, Novo Nordisk and ALK.Dr. Klysner holds a Ph.D. from Technical University of Denmark combined with an Industrial Scientist Research Degree from the Danish Academy of Technical Sciences, a M.Sc. degree in Biochemistry from the University of Copenhagen and a B.Sc. in sports from the University of Copenhagen.Finally, Dr. Klysner is author/co-author of numerous patents and scientific publications in (inter)-national peer-reviewed medical journals.

I am deeply grateful to have had the opportunity to build Amarna to where it is today. In my new role as member of the Supervisory Board, my efforts will be towards helping raise the awareness of Amarna and its SVec gene delivery vector platform and using it to help build a robust pipeline, said Ben van Leent. I have full confidence that Steen, a very passionate and talented leader, will provide the leadership and expertise needed to guide Amarna through the next phases of growth. I look forward to working with Steen to drive forward Amarnas product candidates.

Caption: Steen KlysnerFor high resolution please click the image.

About SV40 vectors: A key to the success of gene therapyToday gene therapy enables the development of a next wave of treatments, with potential to not only treat but also to cure a number of major diseases. Key to the success of gene therapy is the efficient delivery of therapeutic genes into target cells, which is an ability that naturally evolved in viruses, rendering them ideally suited for gene delivery.The Simian virus 40 (SV40) strictly replicates in its natural host, macaque monkeys. The virus cannot replicate in humans and doesnt elicit an immune response, which makes it ideal for developing effective gene therapies. However, the clinical use of SV40 vectors has been hampered by production and safety issues. Amarna has solved this, by developing a novel proprietary SuperVero production cell line and the SVec gene delivery platform.Importantly, SVec can be used to efficiently induce immune tolerance to self-antigens driving degenerative, inflammatory and autoimmune human diseases. Amarna aims to develop SVec-based reverse vaccines for major indications such as neurodegenerative and psychiatric diseases (NDPs), atherosclerotic cardiovascular disease (ACD), obesity, diabetes mellitus (DM), arthritis and chronic obstructive pulmonary disease (COPD).

About Amarna TherapeuticsAmarna Therapeutics is a privately held Biotech company founded in 2008. Its head office is located in Leiden (The Netherlands), and its research facility in Seville (Spain). The company has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas.In October 2019, Amarna secured 10 million in new equity to progress its SVec platform towards clinical studies. The financing round was led by Flerie Invest AB, a Swedish investment company, together with existing shareholders and an innovation credit from the Netherlands Enterprise Agency (RVO.nl).

Contacts

Amarna TherapeuticsSteen Klysner, CEOThis email address is being protected from spambots. You need JavaScript enabled to view it.

LifeSpring Life Sciences Communication, AmsterdamLon Melens+31 6 538 16 427This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Humans; Simian virus 40; Netherlands; Genetic Therapy; Immunotherapy; Gene Transfer Techniques; Immune Tolerance

Published by B3C newswire

Visit link:
Dutch Amarna Therapeutics Announces the Appointment of Steen Klysner as Chief Executive Officer - b3c newswire

Read More...

Spirovant CEO Joan Lau Named Finalist for EY Entrepreneur of The Year in Greater Philadelphia – GlobeNewswire

Thursday, September 3rd, 2020

PHILADELPHIA, PA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, todayannounced that its CEO, Joan Lau, PhD, has been named finalist for the Ernst & Young LLP (EY US) Entrepreneur of the Year 2020 Award in the Greater Philadelphia area. The award honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. Award winners will be announced through a special virtual event in early October.

I am sincerely honored to be named a finalist for the EY Entrepreneur of the Year and to represent our terrific company, our talented team, our inspiring patients, and all the innovative entrepreneurs and scientists in this great region, said Lau. The successes and accomplishments of Spirovant, including being acquired twice in 2019, have resulted from the talent, steadfastness and dedication of our rapidly growing team. These truly exceptional individuals power our mission to deliver innovative gene therapy treatments to patients who have no other options. I thank EY for this honor and its support of entrepreneurialism in Greater Philadelphia and throughout the world.

About EY Entrepreneur of the Year

Entrepreneur of The Year is one of the preeminent competitive award programs for entrepreneurs and leaders of high-growth companies. The nominees are evaluated based on six criteria: overcoming adversity; financial performance; societal impact and commitment to building a values-based company; innovation; and talent management. Since its launch, the program has expanded to recognize business leaders in more than 145 cities in over 60 countries around the world.

Founded and produced by Ernst & Young LLP, the Entrepreneur of The Year Awards are nationally sponsored by SAP America and the Kauffman Foundation. In Greater Philadelphia, sponsors also include PNC Bank, DFIN, SolomonEdwards Group, Ballard Spahr LLP, Morgan, Lewis & Bockius LLP, Murray Devine & Company and Pepper Troutman LLP.

About Spirovant Sciences, Inc.Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other genetic lung diseases. The company's current investigational gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis. Spirovant is advancing programs for cystic fibrosis with both AAV and lentivirus vectors. Spirovant is a wholly owned subsidiary of Sumitovant Biopharma Ltd., which is itself a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Spirovant is located inPhiladelphia, PA.More information is available athttps://www.spirovant.com/.

About Sumitovant BiopharmaLtd.Sumitovant is a global biopharmaceutical company with offices inNew York CityandLondon. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sumitovant is the majority shareholder of Myovant and Urovant, and wholly owns Enzyvant, Spirovant andAltavant. Sumitovant'spipeline is comprised of early- through late-stage investigational medicines across a range of disease areas targeting high unmet need. For further information about Sumitovant please visithttps://www.sumitovant.com/.

About Sumitomo Dainippon Pharma Co., Ltd.Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies inJapan, operating globally in major pharmaceutical markets, includingJapan, the U.S.,Chinaand the European Union. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website athttps://www.ds-pharma.com/.

Media ContactJennifer Guinan

Sage Strategic Marketing

610.410.8111

Jennifer@sagestrat.com

Read the original:
Spirovant CEO Joan Lau Named Finalist for EY Entrepreneur of The Year in Greater Philadelphia - GlobeNewswire

Read More...

‘Moondust’ carnation uses genetic engineering to achieve its blue color – Batesville Daily Guard

Wednesday, September 2nd, 2020

The search for flowers with shades and hues different from what nature provides has been ongoing since humankind discovered the intricacies of plant breeding. But there are limits to the color range that can be achieved using traditional breeding techniques. For example, blue pigments are lacking from many plants.

But science now allows breeders to extend the natural range of colors, using genetic engineering. Moondust carnation, first grown commercially in 1997, is a mini-carnation with purple-mauve flowers that gets its blue color from petunia genes grafted into the DNA of the carnation.

Twelve scientists at an Australian company called Florigene labored for a decade to isolate the gene responsible for blue color in petunia and then transfer it into the carnation. To date, they have released five carnations with the "Moon" prefix, all with varying shades of mauve, blue, violet or purple.

Flower color expression is caused by the subtle blending of pigments contained in the vacuoles (think of vacuoles as storage closets in the cell) and plastid bodies (think of these as like chlorophyll, but with a color other than green) suspended in the cell sap. Just as the man at the paint store blends different pigments to a neutral base to color paint, flower color is caused by the subtle blends of several pigments.

But roses, carnations, lilies and orchids all lack a class of blue pigments called delphinidins, named after the violet-blue we see in delphinium. The gene for delphinidin production is what the Floragene scientists removed from petunia and transferred to the carnation.

The development of the blue carnation was not the primary goal of the research team; no, they wanted to make a blue rose. But, transplanting genes is easy to say but hard to do in the lab, so they honed their techniques on carnations a much easier species to manipulate than roses. The team has not given up on the idea of a blue rose, but it is now exploring the possibility of inserting genes from sea anemones into the rose to create the blue shades. The petunia gene didnt work in roses.

You may be thinking by now, "Ive seen blue carnations for years. Whats new about this?" True, there have been blue carnations available since the 1970s, but their blue was due to food color, not natural pigments.

Scott Admire with Little Rocks United Wholesale Florists said they used to dye white carnations shipped in from cut flower growers in Central and South America. The carnations would have to be shipped in as a "dry pack," exposed to neither water nor the floral preservative silver thiosulphate. The carnations would then suck in the pigment-laden water with a good deal of it ending up in the petals, turning the flowers the shade of blue you see atop a decorated birthday cake.

Carnation flowers sometime get "sleepy" and curl up. This is caused by the production of a plant growth hormone called ethylene, which is a part of the natural aging process in flower development. Cut flower growers combat this by using the silver-containing floral preservative that stops the production of ethylene. Floragene scientists are currently seeking clearance to introduce a line of plants that do not produce ethylene, thus eliminating the need for the silver thiosulphate treatment.

This ethylene-blocking technology is not new, and in fact, an Arkansas boy Dr. Randy Woodson from Fordyce and now a dean at Purdue University responsible for the agricultural research program patented a technique in the early 1990s using the "anti-sense" procedure. Using this technique, the gene for ethylene production is switched end-for-end in the DNA strand, rendering it inoperative. It's not clear if the Floragene technique uses this same "anti-sense" technology.

Are the scientists involved in creating genetically modified plants playing God? What about environmental concerns? For the former question, my theological credentials are suspect, but to the latter question I feel confident there is no significant environmental risk in growing blue carnations. The plants are essentially pollen sterile and carnations are harvested in the tight-bud stage, so the likelihood of out-crossing with wild carnations is remote.

See the original post:
'Moondust' carnation uses genetic engineering to achieve its blue color - Batesville Daily Guard

Read More...

Chile poised to tackle food shortages and climate change with ‘Golden Apple’ and other CRISPR-edited crops – Genetic Literacy Project

Wednesday, September 2nd, 2020

Chiles intense political unrest exacerbated by months of COVID-19 quarantine has temporarily overshadowed a relentless environmental, farming crisis: an intense droughtthe worst in the countrys history now moving into its tenth year. The last few months have offered a temporary respite, with rains reaching average levels. But Chile is in desperate need of longer term responses to worsening climactic conditions that threaten to intensify existing food shortages and jeopardize the nations vital agriculture industry.

Biochemist and president of the Chilean Society of Plant Biology Dr. Claudia Stange believes she is part of the solution. Climate change is here to stay, she believes, so its time to mobilize genetic technology and adapt. Stange and her colleagues at the University of Chile are gene editing new varieties of apple, kiwi and tomato to improve their nutritional content and resistance to drought and saline soils.

This is not the first major effort to harness CRISPR and and transgenics (GMOs) to improve the environmental hardiness or nutritional content of crops. Golden Rice, recently approved for roll out in the Philippines after more than two decades of stops and starts, is a humanitarian project initiated by university scientists to generate a GMO rice high in beta carotene, a precursor to vitamin A. Vitamin A is largely absent from the diets of millions of people in southeast Asia. This deficiency is to blame for 250 000to500 000 cases of childhood blindness every year, with half of them ending in death, according to the World Health Organization (WHO).

Dr. Stanges first major project, launched in 2011 and financed with public funds, had a similar goal to that of Golden Rice: to develop an apple genetically modified to synthesize carotenoids. Due to technical constraints and an inability to get similar results using conventional plant breeding methods, genetic engineering was recognized as the best tool for producing what came to be known as the Golden Apple.

If the project is successful, it could be a major economic and health coup for Chile. It is the worlds fourth largest exporter of apples, so improving the nutritional profile of exported varieties would boost its apple industry and benefit consumers worldwide, Stange told me:

Today consumers are looking for foods that are functional, that means, with a higher content of antioxidants, vitamins, etc. Those characteristics would be fulfilled by our apples with the highest content of carotenoids -which are provitamin A molecules- and antioxidants that counteract various diseases and aging.

The Golden Apple project successfully developed transgenic lines of biofortified apple seedlings years ago, but commercializing it was another matter. Although the development and cultivation of GMO crops like corn, soybean and canola is routine in South American countries including Brazil and Argentina, progress in Chile has been slowed by regulatory obstacles and political opposition to recombinant DNA technology.

Although the country imports large quantities of grain harvested from GMO plants in other countries, Chiles biotech regulations would have prohibited the commercialization of home-grown Golden Apples. Chile currently exports locally cultivated GMO corn, soybean and canola seeds, mostly to the United States, Canada and South Africa. Facing regulatory obstacles, financing for the Golden Apple project dried up by 2014, bringing the research to an unceremonious end.

But the Golden Apple was recently given a faint breath of life. Stange was blocked in bringing her bio-fortified apple to market because it was transgenicit involved the transfer of genes from one species to another. But with advances in gene editing, specifically CRISPR, a technique that has fueled development of a new generation of improved crops, an apple with similar traits could be developed without the use of foreign genes. Chile is now growing gene-edited cereal, vegetable and fruit crops in field trials, although there is as yet no path to commercialization

There are crucial differences between gene editing and older genetic modification technology, Stange explained:

In GMOs, one or more genes from another plant or organism are inserted into a plant of interest so that gene, when expressed, gives it beneficial traits the original plant didnt havefor example, the production of provitamin-A, resistance to drought or pathogens.

In gene editing, molecular biology strategies are also used, but in this case its to avoid that a specific gene is expressed in the plant of interest. By specifically editing or mutating that gene, the plant presents positive traits that it didnt previously have.They [genetic modification and gene editing] are two strategies that seek the same end. Only in the last one there is no exogenous DNA material. For this reason, its more easily accepted in countries where GMOs arent.

After Argentina became the first country to green light gene editing research for agricultural purposes in 2015, Chile followed in 2018 with a similar rule that allows the techniques to be used as long as no transgenes are added to the target plant. Brazil, the United States, Australia, Canada, Colombia, Israel, Japan and other countries subsequently enacted their own gene editing regulations.

Building on their earlier research, Stange and her team expanded work on Golden Apples in 2018, but this time with CRISPR. These next-generation apples will not only provide high levels of Vitamin A and more antioxidants, they will resist browning, which reduces food wastethe same effect achieved by the Arctic apple, developed using a different genetic engineering technique in Canada.

To date we are selecting apple seedlings that have the desired traits: this means, that they have edited the genes of interest, that produce less browning, higher carotenoid content and that are not GMOs. At the end of the year we will be able to have the first seedlings to be transferred to Los Olmos nursery, where they will continue the evaluation in the greenhouse and field.

In the meantime, our team will continue to generate and select more lines so as to have a large number of plants that allows us to choose the best ones when they produce fruit, Stange adds about the project financed by CORFO and carried out in association with the Biofrutales Consortium and Vivero Los Olmos.

These apples wont reach our tables for a while, however. Stange estimated that it will take five years to select the best genotypes of edited apple trees, before taking them to field production.

In March 2020, Stanges laboratory launched another effort designed to address the impact of climate change on regional agricultural production: Proyecto Anillo (Ring Project) Plant Abiotic Stress for a Sustainable Agriculture (PASSA), financed by ANID. The project was developed with the help of Drs. Michael Handford and Lorena Norambuena at the University of Chiles Center for Molecular Biology, in association with Dr. Juan Pablo Martnez from the Institute of Agricultural Research (INIA) and Dr. Ricardo Tejos from Arturo Prat University.

PASSA aims to develop drought- and salt-tolerant tomato and kiwi rootstocks with CRISPR, directly addressing the water emergency situation that is gradually worsening in Chile. Tomatoes are the most consumed vegetable globally and in Chile. The South American nation is also the third largest kiwi exporter after New Zealand and Italy. Shielding these crops from increasing water scarcity and desertification is therefore an essential objective.

According to Stange:

Tomato and kiwi crops are very relevant to the countrys economy. In the case of tomato, well study the traits of the Poncho negro, a Chilean variety originating in the Azapa Valley (Arica) that has a high salinity tolerance and whose genetic breeding would increase the productivity of tomato 7742 (seminis), the most produced and marketed variety in Chile. [I]t can be grafted onto Poncho Negro.

Regarding kiwis, we will seek to increase salinity and drought tolerance of varieties used as rootstocks, to improve the productivity of Hayward commercial kiwi plants.

While the Golden Apple project requires established, fruit-producing trees, fruits are not needed to grow young kiwi and tomato plants; they can be evaluated at the laboratory and greenhouse level under conditions of drought and salinity.

Unfortunately, quarantine has forced the researchers to prioritize bioinformatic activities over laboratory experiments, delaying the project for up to six months. With this setback, it could take three years to edit the plants and evaluate them in field trials.

There is another technical obstacle that must be surmounted as well: adapting crops originating in other parts of world to local conditions:

Currently the new varieties are acquired by paying royalties to foreign companies.

This implies bringing those varieties [to Chile] and waiting a few seasons until they adapt to our edaphoclimatic conditions, with the expectation that they will produce the fruits as they are produced where they were generated. This is a risk. In our case, they are varieties already produced and marketed in Chile to which we will add these new traits.

Stange believes that the future for genetically engineered fruit, vegetables and grains will be brighter than the recent past. GMO crops are gradually being embraced and there is a growing global trend outside of precautionary-obsessed Europe towards relatively lax regulatory oversight of CRISPR gene editing. That could allow for the commercialization of new consumer-focused crop varieties, she says.

The benefit that these biofortified plants bring will overcome the conceptual reluctance to GMOs, especially in countries that appreciate the health value that these types of improved products give them. The need will make countries join the incorporation of GM and edited plant crops.

Daniel Norero is a science communications consultant and fellow at the Cornell Alliance for Science. He studied biochemistry at the Catholic University of Chile. Follow him on Twitter @DanielNorero

Read the original here:
Chile poised to tackle food shortages and climate change with 'Golden Apple' and other CRISPR-edited crops - Genetic Literacy Project

Read More...

The promise and perils of synthetic biology take center stage in a fast-paced new Netflix series – Science Magazine

Wednesday, September 2nd, 2020

Christian DitterNetflix6 episodes

The first season of the Netflix series Biohackers, consisting of six episodes released on the streaming platform on 20 August, tells a fictional tale centered around the sociotechnological movement known as do-it-yourself (DIY) biology, in which amateurs, professionals, anarchists, and civic-minded citizens push the boundaries of mainstream biology. The shows main characters include a wealthy biopharmaceutical executive, a group of medical students, a number of stereotypical biohackers making animals glow and plants play music, and a community of transhumanists intent on modifying their bodies for seemingly impractical endeavors.

Whereas biological experimentation was once the sole domain of trained professionals in well-stocked and well-funded institutional labs, the field has been democratized by the emergence of the open-source movement, plummeting sequencing costs, greater access to reagents and devices, the proliferation of online resources, and the emergence of tools and methodologies that enable nonexperts to genetically engineer organisms without years of professional training. [Valid concerns regarding some of the activities associated with the DIY bio community have been voiced by the Presidential Commission for the Study of Bioethical Issues (1).]

Medical student Mia Akerlund (right) meets biohackers pushing the boundaries of mainstream biology.

The show follows Mia Akerlund (played by Luna Wedler), a first-year medical student vying for a position at a prestigious biopharmaceutical firm headed by celebrated professor Tanja Lorenz (Jessica Schwarz). Akerlund and Lorenz clearly have some shared history, as well as their own secrets, although viewers are not privy to the details of either at the start of the series. For much of the first episodes, the relationship between these two enigmatic characters is revealed slowly through both flash-forwards and flashbacks. But we know that a big reveal is coming; the programs official description teases a secret so big it could change the fate of humanity.

Throughout the seasons six fast-paced episodes, the viewer is exposed to technologies and techniques that would be familiar to many professional scientists. And while the time frames of the various experiments conducted are often compressed for dramatic effect, Christian Ditterthe shows creator, writer, director, and showrunnergoes out of his way to present complex science as accurately as possible. In one montage, for example, we watch various biohackers, some with better aseptic technique than others, add reagents to microcentrifuge tubes, load polymerase chain reaction machines, and examine gels to assess whether they have accurately created a desired genomic sequence. In another scene, a student suffering from a degenerative disease seeks to develop his own cure in a secret lab, where he can work without burdensome oversight. The student injects himself with an unknown liquid, his purported cure. Here, the shows dialogue surrounding the cure and its antidote (to be administered if things go wrong) offers insight into how RNA interference therapies work.

But the show also serves as a pedagogical vehicle to raise many timely and interesting ethical, legal, and social concerns. From bioluminescent mammals to the collection of genetic material for clinical trials, the series storyline highlights how cavalierly we sometimes approach genomic data and genetic engineering. Later episodes depict even more egregious examples of biohacking, including organisms modified to transmit viruses as efficiently as possible. At one point, a character suggests that the ends of her research justify the experimental means, even when her methods demonstrate a gross disregard for test subjects who may suffer as a result.

The show also offers insight into some of the motivations that drive DIY biology efforts. For example, in one scene, a confidant of Akerlund expresses dismay that Lorenz is willing to sell a cheaply acquired drug to desperate patients for inflated prices. Such frustrations are what drive many citizens operating outside traditional institutions to develop their own pharmaceutical solutions.

It is ironic that Biohackers is set in Germany, one of the few places where genetic engineering experimentation outside of licensed facilities is illegal and can result in a fine or even imprisonment (2). Yet, given all that transpires in the show, one is left with the sense that such measures maybe justified.

References and Notes:1. Presidential Commission for the Study of Bioethical Issues, New directions: The ethics of synthetic biology and emerging technologies (2010).2. Sections 8 and 39 of the German Genetic Engineering Act [Gentechnikgesetz (GenTG)].

The reviewer is at Zvi Meitar Institute for Legal Implications of Emerging Technologies, Herzliya, Israel, and the Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.

Read the original post:
The promise and perils of synthetic biology take center stage in a fast-paced new Netflix series - Science Magazine

Read More...

How Groups of Cells Cooperate to Build Organs and Organisms – The Scientist

Wednesday, September 2nd, 2020

Efforts to use regenerative medicinewhich seeks to address ailments as diverse as birth defects, traumatic injury, aging, degenerative disease, and the disorganized growth of cancerwould be greatly aided by solving one fundamental puzzle: How do cellular collectives orchestrate the building of complex, three-dimensional structures?

While genomes predictably encode the proteins present in cells, a simple molecular parts list does not tell us enough about the anatomical layout or regenerative potential of the body that the cells will work to construct. Genomes are not a blueprint for anatomy, and genome editing is fundamentally limited by the fact that its very hard to infer which genes to tweak, and how, to achieve desired complex anatomical outcomes. Similarly, stem cells generate the building blocks of organs, but the ability to organize specific cell types into a working human hand or eye has been and will be beyond the grasp of direct manipulation for a very long time.

But researchers working in the fields of synthetic morphology and regenerative biophysics are beginning to understand the rules governing the plasticity of organ growth and repair. Rather than micromanaging tasks that are too complex to implement directly at the cellular or molecular level, what if we solved the mystery of how groups of cells cooperate to construct specific multicellular bodies during embryogenesis and regeneration? Perhaps then we could figure out how to motivate cell collectives to build whatever anatomical features we want.

New approaches now allow us to target the processes that implement anatomical decision-making without genetic engineering. In January, using such tools, crafted in my lab at Tufts Universitys Allen Discovery Center and by computer scientists in Josh Bongards lab at the University of Vermont, we were able to create novel living machines, artificial bodies with morphologies and behaviors completely different from the default anatomy of the frog species (Xenopus laevis) whose cells we used. These cells rebooted their multicellularity into a new form, without genomic changes. This represents an extremely exciting sandbox in which bioengineers can play, with the aim of decoding the logic of anatomical and behavioral control, as well as understanding the plasticity of cells and the relationship of genomes to anatomies.

Deciphering how an organism puts itself together is truly an interdisciplinary undertaking.

Deciphering how an organism puts itself together is truly an interdisciplinary undertaking. Resolving the whole picture will involve understanding not only the mechanisms by which cells operate, but also elucidating the computations that cells and groups of cells carry out to orchestrate tissue and organ construction on a whole-body scale. The next generation of advances in this area of research will emerge from the flow of ideas between computer scientists and biologists. Unlocking the full potential of regenerative medicine will require biology to take the journey computer science has already taken, from focusing on the hardwarethe proteins and biochemical pathways that carry out cellular operationsto the physiological software that enables networks of cells to acquire, store, and act on information about organ and indeed whole-body geometry.

In the computer world, this transition from rewiring hardware to reprogramming the information flow by changing the inputs gave rise to the information technology revolution. This shift of perspective could transform biology, allowing scientists to achieve the still-futuristic visions of regenerative medicine. An understanding of how independent, competent agents such as cells cooperate and compete toward robust outcomes, despite noise and changing environmental conditions, would also inform engineering. Swarm robotics, Internet of Things, and even the development of general artificial intelligence will all be enriched by the ability to read out and set the anatomical states toward which cell collectives build, because they share a fundamental underlying problem: how to control the emergent outcomes of systems composed of many interacting units or individuals.

Many types of embryos can regenerate entirely if cut in half, and some species are proficient regenerators as adults. Axolotls (Ambystoma mexicanum) regenerate their limbs, eyes, spinal cords, jaws, and portions of the brain throughout life. Planarian flatworms (class Turbellaria), meanwhile, can regrow absolutely any part of their body; when the animal is cut into pieces, each piece knows exactly whats missing and regenerates to be a perfect, tiny worm.

The remarkable thing is not simply that growth begins after wounding and that various cell types are generated, but that these bodies will grow and remodel until a correct anatomy is complete, and then they stop. How does the system identify the correct target morphology, orchestrate individual cell behaviors to get there, and determine when the job is done? How does it communicate this information to control underlying cell activities?

Several years ago, my lab found that Xenopus tadpoles with their facial organs experimentally mixed up into incorrect positions still have largely normal faces once theyve matured, as the organs move and remodel through unnatural paths. Last year, a colleague at Tufts came to a similar conclusion: the Xenopus genome does not encode a hardwired set of instructions for the movements of different organs during metamorphosis from tadpole to frog, but rather encodes molecular hardware that executes a kind of error minimization loop, comparing the current anatomy to the target frog morphology and working to progressively reduce the difference between them. Once a rough spatial specification of the layout is achieved, that triggers the cessation of further remodeling.

The deep puzzle of how competent agents such as cells work together to pursue goals such as building, remodeling, or repairing a complex organ to a predetermined spec is well illustrated by planaria. Despite having a mechanistic understanding of stem cell specification pathways and axial chemical gradients, scientists really dont know what determines the intricate shape and structure of the flatworms head. It is also unknown how planaria perfectly regenerate the same anatomy, even as their genomes have accrued mutations over eons of somatic inheritance. Because some species of planaria reproduce by fission and regeneration, any mutation that doesnt kill the neoblastthe adult stem cell that gives rise to cells that regenerate new tissueis propagated to the next generation. The worms incredibly messy genome shows evidence of this process, and cells in an individual planarian can have different numbers of chromosomes. Still, fragmented planaria regenerate their body shape with nearly 100 percent anatomical fidelity.

Permanent editingof the encoded target morphology without genomic editing reveals a new kind of epigenetics.

So how do cell groups encode the patterns they build, and how do they know to stop once a target anatomy is achieved? What would happen, for example, if neoblasts from a planarian species with a flat head were transplanted into a worm of a species with a round or triangular head that had the head amputated? Which shape would result from this heterogeneous mixture? To date, none of the high-resolution molecular genetic studies of planaria give any prediction for the results of this experiment, because so far they have all focused on the cellular hardware, not on the logic of the softwareimplemented by chemical, mechanical, and electrical signaling among cellsthat controls large-scale outcomes and enables remodeling to stop when a specific morphology has been achieved.

Understanding how cells and tissues make real-time anatomical decisions is central not only to achieving regenerative outcomes too complex for us to manage directly, but also to solving problems such as cancer. While the view of cancer as a genetic disorder still largely drives clinical approaches, recent literature supports a view of cancer as cells simply not being able to receive the physiological signals that maintain the normally tight controls of anatomical homeostasis. Cut off from these patterning cues, individual cells revert to their ancient unicellular lifestyle and treat the rest of the body as external environment, often to ruinous effect. If we understand the mechanisms that scale single-cell homeostatic setpoints into tissue- and organ-level anatomical goal states and the conditions under which the anatomical error reduction control loop breaks down, we may be able to provide stimuli to gain control of rogue cancer cells without either gene therapy or chemotherapy.

During morphogenesis, cells cooperate to reliably build anatomical structures. Many living systems remodel and regenerate tissues or organs despite considerable damagethat is, they progressively reduce deviations from specific target morphologies, and halt growth and remodeling when those morphologies are achieved. Evolution exploits three modalities to achieve such anatomical homeostasis: biochemical gradients, bioelectric circuits, and biophysical forces. These interact to enable the same large-scale form to arise despite significant perturbations.

N.R. FULLER, SAYO-ART, LLC

BIOCHEMICAL GRADIENTS

The best-known modality concerns diffusible intracellular and extracellular signaling molecules. Gene-regulatory circuits and gradients of biochemicals control cell proliferation, differentiation, and migration.

BIOELECTRIC CIRCUITS

The movement of ions across cell membranes, especially via voltage-gated ion channels and gap junctions, can establish bioelectric circuits that control large-scale resting potential patterns within and among groups of cells. These bioelectric patterns implement long-range coordination, feedback, and memory dynamics across cell fields. They underlie modular morphogenetic decision-making about organ shape and spatial layout by regulating the dynamic redistribution of morphogens and the expression of genes.

BIOMECHANICAL FORCES

Cytoskeletal, adhesion, and motor proteins inside and between cells generate physical forces that in turn control cell behavior. These forces result in large-scale strain fields, which enable cell sheets to move and deform as a coherent unit, and thus execute the folds and bends that shape complex organs.

The software of life, which exploits the laws of physics and computation, is enabled by chemical, mechanical, and electrical signaling across cellular networks. While the chemical and mechanical mechanisms of morphogenesis have long been appreciated by molecular and cell biologists, the role of electrical signaling has largely been overlooked. But the same reprogrammability of neural circuits in the brain that supports learning, memory, and behavioral plasticity applies to all cells, not just neurons. Indeed, bacterial colonies can communicate via ionic currents, with recent research revealing brain-like dynamics in which information is propagated across and stored in a kind of proto-body formed by bacterial biofilms. So it should really come as no surprise that bioelectric signaling is a highly tractable component of morphological outcomes in multicellular organisms.

A few years ago, we studied the electrical dynamics that normally set the size and borders of the nascent Xenopus brain, and built a computer model of this process to shed light on how a range of various brain defects arise from disruptions to this bioelectric signaling. Our model suggested that specific modifications with mRNA or small molecules could restore the endogenous bioelectric patterns back to their correct layout. By using our computational platform to select drugs to open existing ion channels in nascent neural tissue or even a remote body tissue, we were able to prevent and even reverse brain defects caused not only by chemical teratogenscompounds that disrupt embryonic developmentbut by mutations in key neurogenesis genes.

Similarly, we used optogenetics to stimulate electrical activity in various somatic cell types totrigger regeneration of an entire tadpole tailan appendage with spinal cord, muscle, and peripheral innervationand to normalize the behavior of cancer cells in tadpoles strongly expressing human oncogenes such as KRAS mutations. We used a similar approach to trigger posterior regions, such as the gut, to build an entire frog eye. In both the eye and tail cases, the information on how exactly to build these complex structures, and where all the cells should go, did not have to be specified by the experimenter; rather, they arose from the cells themselves. Such findings reveal how ion channel mutations result in numerous human developmental channelopathies, and provide a roadmap for how they may be treated by altering the bioelectric map that tells cells what to build.

We also recently found a striking example of such reprogrammable bioelectrical software in control of regeneration in planaria. In 2011, we discovered that an endogenous electric circuit establishes a pattern of depolarization and hyperpolarization in planarian fragments that regulate the orientation of the anterior-posterior axis to be rebuilt. Last year, we discovered that this circuit controls the gene expressionneeded to build a head or tail within six hours of amputation, and by using molecules that make cell membranes permeable to certain ions to depolarize or hyperpolarize cells, we induced fragments of such worms to give rise to a symmetrical two-headed form, despite their wildtype genomes. Even more shockingly, the worms continued to generate two-headed progeny in additional rounds of cutting with no further manipulation. In further experiments, we demonstrated that briefly reducing gap junction-mediated connectivity between adjacent cells in the bioelectric network that guides regeneration led worms to regenerate head and brain shapes appropriate to other worm species whose lineages split more than 100 million years ago.

My group has developed the use of voltage-sensitive dyes to visualize the bioelectric pattern memory that guides gene expression and cell behavior toward morphogenetic outcomes. Meanwhile, my Allen Center colleagues are using synthetic artificial electric tissues made of human cells and computer models of ion channel activity to understand how electrical dynamics across groups of non-neural cells can set up the voltage patterns that control downstream gene expression, distribution of morphogen molecules, and cell behaviors to orchestrate morphogenesis.

The emerging picture in this field is that anatomical software is highly modulara key property that computer scientists exploit as subroutines and that most likely contributes in large part to biological evolvability and evolutionary plasticity. A simple bioelectric state, whether produced endogenously during development or induced by an experimenter, triggers very complex redistributions of morphogens and gene expression cascades that are needed to build various anatomies. The information stored in the bodys bioelectric circuitscan be permanently rewritten once we understand the dynamics of the biophysical circuits that make the critical morphological decisions. This permanent editing of the encoded target morphology without genomic editing reveals a new kind of epigenetics, information that is stored in a medium other than DNA sequences and chromatin.

Recent work from our group and others has demonstrated that anatomical pattern memories can be rewritten by physiological stimuli and maintained indefinitely without genomic editing. For example, the bioelectric circuit that normally determines head number and location in regenerating planaria can be triggered by brief alterations of ion channel or gap junction activity to alter the animals body plan. Due to the circuits pattern memory, the animals remain in this altered state indefinitely without further stimulation, despite their wildtype genomes. In other words, the pattern to which the cells build after damage can be changed, leading to a target morphology distinct from the genetic default.

N.R. FULLER, SAYO-ART, LLC

First, we soaked a planarian in voltage-sensitive fluorescent dye to observe the bioelectrical pattern across the entire tissue. We then cut the animal to see how this pattern changes in each fragment as it begins to regenerate.

We then applied drugs or used RNA interference to target ion channels or gap junctions in individual cells and thus change the pattern of depolarization/hyperpolarization and cellular connectivity across the whole fragment.

As a result of the disruption of the bodys bioelectric circuits, the planarian regrows with two heads instead of one, or none at all.

When we re-cut the two-headed planarian in plain water, long after the initial drug has left the tissue, the new anatomy persists in subsequent rounds of regeneration.

Cells can clearly build structures that are different from their genomic-default anatomical outcomes. But are cells universal constructors? Could they make anything if only we knew how to motivate them to do it?

The most recent advances in the new field at the intersection of developmental biology and computer science are driven by synthetic living machines known as biobots. Built from multiple interacting cell populations, these engineered machines have applications in disease modeling and drug development, and as sensors that detect and respond to biological signals. We recently tested the plasticity of cells by evolving in silico designs with specific movement and behavior capabilities and used this information to sculpt self-organized growth of aggregated Xenopus skin and muscle cells. In a novel environmentin vitro, as opposed to inside a frog embryoswarms of genetically normal cells were able to reimagine their multicellular form. With minimal sculpting post self-assembly, these cells form Xenobots with structures, movements, and other behaviors quite different from what might be expected if one simply sequenced their genome and identified them as wildtype X. laevis.

These living creations are a powerful platform to assess and model the computations that these cell swarms use to determine what to build. Such insights will help us to understand evolvability of body forms, robustness, and the true relationship between genomes and anatomy, greatly potentiating the impact of genome editing tools and making genomics more predictive for large-scale phenotypes. Moreover, testing regimes of biochemical, biomechanical, and bioelectrical stimuli in these biobots will enable the discovery of optimal stimuli for use in regenerative therapies and bioengineered organ construction. Finally, learning to program highly competent individual builders (cells) toward group-level, goal-driven behaviors (complex anatomies) will significantly advance swarm robotics and help avoid catastrophes of unintended consequences during the inevitable deployment of large numbers of artificial agents with complex behaviors.

Understanding how cells and tissues make real-time anatomical decisions is central to achieving regenerative outcomes too complex for us to manage directly.

The emerging field ofsynthetic morphology emphasizes a conceptual point that has been embraced by computer scientists but thus far resisted by biologists: the hardware-software distinction. In the 1940s, to change a computers behavior, the operator had to literally move wires aroundin other words, she had to directly alter the hardware. The information technology revolution resulted from the realization that certain kinds of hardware are reprogrammable: drastic changes in function could be made at the software level, by changing inputs, not the hardware itself.

In molecular biomedicine, we are still focused largely on manipulating the cellular hardwarethe proteins that each cell can exploit. But evolution has ensured that cellular collectives use this versatile machinery to process information flexibly and implement a wide range of large-scale body shape outcomes. This is biologys software: the memory, plasticity, and reprogrammability of morphogenetic control networks.

The coming decades will be an extremely exciting time for multidisciplinary efforts in developmental physiology, robotics, and basal cognition to understand how individual cells merge together into a collective with global goals not belonging to any individual cell. This will drive the creation of new artificial intelligence platforms based not on copying brain architectures, but on the multiscale problem-solving capacities of cells and tissues. Conversely, the insights of cognitive neurobiology and computer science will give us a completely new window on the information processing and decision-making dynamics in cellular collectives that can very effectively be targeted for transformative regenerative therapies of complex organs.

Michael Levinis the director of the Allen Discovery Center at Tufts University and Associate Faculty at Harvard Universitys Wyss Institute. Email him atmichael.levin@tufts.edu. M.L. thanks Allen Center Deputy DirectorJoshua Finkelsteinfor suggestions on the drafts of this story.

Originally posted here:
How Groups of Cells Cooperate to Build Organs and Organisms - The Scientist

Read More...

Viral Vector Manufacturing Market Forecast to Reach $1.47 Billion by 2025 – ResearchAndMarkets.com – Business Wire

Wednesday, September 2nd, 2020

DUBLIN--(BUSINESS WIRE)--The "Viral Vector Manufacturing Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

The global viral vector manufacturing market is projected to grow at a CAGR of 22.09% to reach a market size of US$1,469.144 million in 2025 from US$443.592 million in 2019.

The viral vector market is primarily being driven by the growing adoption of adenoviral vectors, lentiviral vectors, as well as retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic gene into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell one of the preferred treatment options for most chronic diseases, which is known as Gene therapy.

Furthermore, the growing number of clinical trials, the increasing number of gene therapy, and the expanding cognizance of effective mode of disease treatment are further expected to drive the growth of the viral vector manufacturing market during the forecast period. Since vector designing, production, packaging, and release testing is subject to limited availability and faced with challenges due to the complex nature of technologies and platform and thus many players in this space often endeavor in striking strategic collaboration and acquisitions that cover many aspects like the delivery of clinical grade product under its ambit, to facilitate the successful collaboration development of viral agent-based products.

Moreover, the efficient ability to express the therapeutic genes and non-pathogenic nature is another factor that is responsible for driving the growth of this market. The other key factors that are expected to drive the growth of the market are the increasing investment in the biopharmaceutical production coupled with the growing aging population, healthcare expenditure, technological advancement, especially in the genetic engineering segment.

Moreover, the increasing accessibility of healthcare facilities, the growing demand for treatment of disease due to the increasing global burden of diseases are a few of the other factors that are poised to drive the growth of this market during the forecast period. Nevertheless, despite the transitioning of this niche industry to high manufacturing is one such factor that may restrain the growth of the market to a certain extent.

Therefore, with such growing recognition of the importance of viral vectors, various developments are taking place in the viral vector manufacturing market. For instance, in June 2020, it was announced by Emergent BioSolutions Inc. (NYSE: EBS) which is a global life sciences company that it is going to invest $75 Million in Canton Site and expand viral vector and gene therapy capability facilitating the reinforcement of its contract development and manufacturing (CDMO) capabilities.

Again, in June 2020, Oxford Biomedica (LSE: OXB) which is a major gene and cell therapy group, announced that it has signed an agreement of collaboration with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization that has been established to provide the first strategic vaccine development and progressive manufacturing capability in the UK. Under this 5-year agreement, the organization will work towards enabling the manufacture of vaccines that are based on viral vector, to contribute towards a swift growth in the domestic capacity for this specialized field of vaccine manufacturing.

In April 2020, Merck KGaA (FWB: MRK) a leading science and technology company announced that a 100 million facility, second in Carlsbad, California USA that is intended to boost its BioReliance viral and gene therapy service offering to help their customers to aid their customers to commercialize the gene therapies that are brought about by viral vectors concomitantly helping innovators scale up their production that is in tandem with the quantum that allows them to reach out to more patients.

Earlier, in January 2020, the launch of ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene) in Germany was announced by bluebird bio, Inc. (Nasdaq: BLUE). ZYNTEGLO is a one-time gene therapy that has been specifically developed for patients aged 12 years and older with transfusion-dependent -thalassemia (TDT) who do not possess 0/0 genotype.

In December 2019, it was announced that a leading supplier of services and technologies for the life sciences industry called Novasep launched oXYgene which is a fully integrated offering for the construction of facilities dedicated towards customers to aid them in their viral vector production.

In October 2019, it was reported that GE Healthcare Life Sciences which has now rebranded itself as Cytiva, was about to launch the KUBio box which is an adaptable, flexible and fully integrated environment for biomanufacturing to accelerate the production gene therapies based on of viral vector. These latest additions were intended to bring gene therapies swiftly to the market thereby contributing to the increased capacity in the viral vector area.

In March 2018, it was reported that Sartorius Stedim Biotech SA (SSB), which is a major international technology partner supplier of products and services biopharmaceutical industry has been selected by ABL Europe as its chief supplier of single-use systems whereby the new viral vector manufacturing capacity has been started in Strasbourg at its European facility. ABL Europe, a subsidiary of ABL Inc. provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch.

Key Topics Covered

1. Introduction

1.1. Market Definition

1.2. Market Segmentation

2. Research Methodology

2.1. Research Data

2.2. Assumptions

3. Executive Summary

3.1. Research Highlights

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.4. Industry Value Chain Analysis

5. Viral Vector Manufacturing Market Analysis, By Type

5.1. Introduction

5.2. Retroviral vectors

5.3. Lentiviral Vectors

5.4. Adenoviral Vectors

5.5. Others

6. Viral Vector Manufacturing Market Analysis, By Application

6.1. Introduction

6.2. Vaccinology

6.3. Gene Therapy

7. Viral Vector Manufacturing Market Analysis, By End-User

7.1. Introduction

7.2. Pharmaceutical & Biotechnology Companies

7.3. Research Institutes

7.4. Contract Research Organizations

8. Viral Vector Manufacturing Market Analysis, by Geography

8.1. Introduction

8.2. North America

8.3. South America

8.4. Europe

8.5. The Middle East & Africa

8.6. Asia-Pacific

9. Competitive Environment and Analysis

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. Company Profiles

10.1. Sirion-Biotech GmbH

10.2. Vigene Biosciences

10.3. Batavia Biosciences B.V.

10.4. Virovek

10.5. Lonza

10.6. Vector Biolabs

10.7. Cobra Biologics

10.8. MaxCyte, Inc.

10.9. Genelux

10.10. BioNTech SE

For more information about this report visit https://www.researchandmarkets.com/r/c3nfai

View original post here:
Viral Vector Manufacturing Market Forecast to Reach $1.47 Billion by 2025 - ResearchAndMarkets.com - Business Wire

Read More...

CAR T-Cell Optimization Starts in Production, Extends to Therapy – Genetic Engineering & Biotechnology News

Wednesday, September 2nd, 2020

Just as heat-seeking missiles race toward the infrared signatures of their targets, chimeric antigen receptor (CAR) T cells home in on cancer-associated or -specific antigens. Once the antigens are engaged, CAR T cells let fly with cytotoxic flak, granules containing perforin and granzymes, while activating supplementary tumor-killing mechanisms such as stromal sensitization and macrophage polarization. It is to be hoped that by the time the cytotoxic smoke clears, the cancer will have been destroyed.

The development of CAR T cells has revolutionized adoptive cellular therapies against cancer. CARs are genetically engineered to combine antigen- or tumor-specific-binding with T-cell activating domains. T cells, obtained from the patient (autologous cells) or from a healthy donor (allogeneic cells), are typically transduced with an engineered vector, expanded, and infused back into the patient for tumor eradication.

In the 10 years since its inception, the CAR T-cell field has progressed rapidly. Two CAR T-cell products have been approved for clinical use, and many more products are undergoing clinical trials or are in development. Although the field initially focused on B-cell malignancies, it is now advancing on solid tumors.

Despite its initial success, the CAR T-cell field must find ways to generate products that are potent, affordable, and available. To achieve enduring success, the CAR T-cell field is undertaking a range of initiatives. These include the engineering of bridging proteins for multiantigen targeting; the creation of nonviral allogeneic off-the-shelf products; the organization of vein-to-vein networks; and the development of precisely tuned therapies, that is, precisely timed and dosed therapies.

Cellular therapy is a living drug, declares Steve Shamah, PhD, senior vice president, Obsidian Therapeutics. As with any drug, damage can occur if the therapy is not carefully regulated. Our company focuses on creating controllable cell therapies by engineering CAR T cells or tumor-infiltrating lymphocytes to produce regulatable cytokines and proteins that can enhance functional activity, especially against solid tumors.

For example, the company is developing a platform that armors CAR T cells with immunomodulatory factors such as interleukin-15 (IL-15) or CD40 ligand. Shamah explains, These factors can enhance functional activity by driving T-cell expansion, conferring resistance to immunosuppression, improving antigen presentation, and inducing antigen spread. However, both factors can also produce systemic toxicity. Our technology modulates the level and timing of their activity in a fully controlled, dose-dependent manner using an FDA-approved small-molecule drug.

The Obsidian platform, cytoDRiVE, adds a drug-responsive domain (DRD) onto a therapeutic protein of interest. DRD tags are misfolded or inherently unstable in the cell. However, they can be reversibly stabilized by the binding of approved small-molecule drugs. When the drug is absent, the DRD-tagged protein is turned off. When the drug is present, the DRD-tagged protein is turned on. When DRD tags are in place, the concentration of the small-molecule drug serves as a biological rheostat for controlling the dosing of the therapeutic protein.

Preclinical in vivo mouse studies assessed anti-CD19 CAR T cells that were engineered to express an IL-15-DRD that responded to the FDA-approved drug acetazolamide. In these studies, tumor regression was demonstrated.

Controlling the precise timing and expression level of these immunomodulatory factors in CAR T cells could significantly enhance safety and therapeutic efficacy, concludes Shamah.

Obsidian is currently focusing on the oncology space, but the company is also exploring other areas such as autoimmunity and even the regulation of transcription factors to enable controllable in vivoCRISPR-Cas9 gene editing.

Despite the remarkable success of CAR T-cell therapies, relapses can occur within six months for up to 50% of patients treated with anti-CD19 CAR T-cell therapy.Failures can occur due to loss of CD19 expression or to continued tumor proliferation. Aleta Biotherapeutics has developed a novel technology to reactivate CAR T cells in relapsed patients.

Our approach utilizes antigen-bridging proteins to coat tumors with CD19, says Paul Rennert, PhD, Aletas president and CSO. [The tumors are then] recognized by the patients anti-CD19 CAR T cells, essentially creating a cytotoxic synapse that results in tumor cell death.

To thwart anti-CD19 CAR T-cell therapy relapses, the company developed a bridging protein using the extracellular domain of CD19 and an anti-CD20 antibody domain. CD20 is an antigen present on the majority of B-cell malignancies. Rennert explains that these injected bridging proteins will coat the patients tumor cells with CD19, creating a target to activate or reactivate a patients anti-CD19 CAR T cells.

To show proof-of-principle, the company performed in vivo studies using a half-life-extended form of the bridging protein injected into mice carrying CD20-positive tumor cells and anti-CD19 CAR T cells. Rennert emphasizes, Our studies demonstrated this strategy can be used to reactivate CD19 CAR T cells to prevent and reverse relapses.

Other programs in development include a bridging protein for injection to improve outcomes in multiple myeloma patients treated with CAR T cells, and bridging protein programs for HER2-positive breast cancer patients with central nervous system metastases. The company is preparing investigational new drug applications for its technology and plans to start Phase I trials in 2021.

Assessing whether engineered CAR T-cell and T-cell receptor (TCR) therapies have successfully attacked and penetrated solid tumors (and not normal cells) can be like finding the proverbial needle in the haystack. Traditional methods using immunohistochemistry are useful for immune profiling, but they cannot differentiate engineered versus endogenous cells, points out Christopher Bunker, PhD, senior director of business development, Advanced Cell Diagnostics, a Bio-Techne brand. We developed a means to easily detect and track engineered therapeutic cells and delineate their pharmacokinetics within the tumor microenvironment of intact tumor biopsies, as well as their on-target/off-tumor activity.

Enter RNAscope, an RNA in situ hybridization technology that can enable single-cell spatial transcriptomics. RNAscope, Bunker asserts, is the only off-the-shelf method that can specifically detect engineered CAR T cells and TCR T cells in solid tumor patient biopsies.

Most cell therapies employ lentivirus transduction. Because CAR or TCR transgenes have unique sequences in the viral untranslated regions, these can be used as tags for identification of engineered cell therapies with RNAscope probes. The technology utilizes pools of paired oligos that can be thought of as a ZZ pair, where the paired 3 ends hybridize to ~50 bases of target mRNA, and where the paired 5 ends hybridize to a signal amplification module, which is built through sequential hybridization steps. The signal amplification of paired oligos results in an assay able to detect individual transcripts that appear as visible and quantifiable dots.

Its a little like planting and lighting Christmas trees, quips Bunker. The ZZ pairs plant trees along the mRNA with branches that are decorated either with fluorophores or chromogens. Although the primary technology currently features four colors, the company has developed a HiPlex (12-plex) assay and foresees even higher-plex assays with different detection methods.

We envision assays based on our core technologies that enable spatial analysis of perhaps a hundred transcripts in combination with tens of proteins, Bunker projects. In the context of cell therapy development, these will enable a more comprehensive understanding of tumor biology and immune cell profiles to determine the most effective treatment strategy for a patient, as well as for monitoring efficacy of solid tumor cellular therapies.

Companies developing CAR T-cell products are also eyeing a future involving GMP production. Thus, a critical early question is how to choose the best T-cell medium for manufacturing processes. To test the suitability of a CAR T-cell growing medium, companies must assess factors such as cell viability, cell expansion, cytokine profiles, and cell purity. A medium suitable for a CAR T-cell manufacturing process also needs to support rapid activation and CAR transduction. Additionally, the selected medium needs to be compatible with a variety of donors.

There are many available choices for T-cell culture media ranging from do-it-yourself recipes to commercially available one-size-fits-all complete formulations. CellGenix has developed a novel T-cell medium that avoids the use of human serum. Sebastian Warth, PhD, a senior scientist at CellGenix, explains, To achieve consistent results, human serum requires extensive testing prior to its use for production of cellular products due to lot-to-lot inconsistencies. Since human serum is a limited resource and might not be available in large quantities, it is unfavorable for commercial-scale manufacturing. Furthermore, the human origin of serum poses a certain risk of containing adventitious agents and is, therefore, a risk to the safety of the T-cell therapy product.

The companys TCM GMP-Prototype medium provides a serum-free and xeno-free product for early-onset T-cell expansion. According to Warth, key advantages include promotion of sustained viability, support for expansion of CD4+ and CD8+ T cells, promotion of a central memory and early differentiated memory T-cell phenotype, and maintenance of a high proportion of cytokine-producing cells including polyfunctional cells. Further, it was optimized for and verified with CAR T cells.

While autologous CAR T-cell therapies have proven highly successful, they also require a long and expensive manufacturing process. The dream of being able to utilize off-the-shelf allogeneic T cells is on the horizon.

Devon J. Shedlock, PhD, senior vice president, research and development,Poseida Therapeutics, reports, With our technology, we are able to genetically modify cells to create a fully allogenic, or off-the-shelf, product that does not require additional immunosuppression treatment like earlier generation approaches. We also have developed technology to allow us to make hundreds of doses from a single manufacturing run from healthy donors, thereby dropping the cost substantially.

According to Shedlock, the technology consists of three key aspects: 1) the piggyback DNA Modification System, 2) the Cas-CLOVER site-specific gene editing system, and 3) the Booster Molecule.

The PiggyBac DNA Modification System is a nonviral technology for stably integrating genes into DNA. One key feature is that piggyBac preferentially inserts into less mature T cells, enabling the production of therapies that have a high proportion of stem cell memory T cells, or Tscm cells.

Viral technologies are virtually excluded from Tscm cells, Shedlock states. However, Tscm cells are the ideal cell type for cell-based therapies because they have the ability to engraft and potentially last a lifetime, can produce wave after wave of more differentiated cells to attack the tumor, and are much more tolerable with low levels of adverse events compared to other CAR T-cell products.

The companys Cas-CLOVER gene editing technology is a hybrid gene editing technology used to edit the T cells to make allogeneic products. Cas-CLOVER works well in resting T cells, which is important in preserving Tscm cells in a fully allogeneic CAR T-cell product, Shedlock elaborates. It also is a very precise and clean system. This is a particularly important safety issue for allogeneic products that may be given to many patients.

The Booster Molecule is added during manufacture and is temporarily expressed on the cell surface to allow cell stimulation. Normally when allogeneic CAR T-cell products are created, the T-cell receptor must be eliminated to avoid the graft-versus-host reaction, which is a major safety issue. Importantly, this booster stimulation occurs while preserving the Tscm phenotype.

Poseida Therapeutics expects to launch a clinical trial for its multiple myeloma allogeneic product late this year or early next year. The company will also begin clinical trials later in 2021 on its pan-solid tumor allogeneic program.

Creation of partnerships can help drive development of CAR T-cell therapeutics from concept through clinical trials. Advanced therapies require advanced supply chain and data management, advises Minh Hong, PhD, head of autologous cell therapy, Lonza Pharma & Biotech. Prior biopharmaceutical models of mass production and distributionand the systems that support themare not effective for personalized therapeutics. As manufacturing demand increases for autologous cell therapies, there is an overarching need to both industrialize and simplify the entire supply chain ecosystem.

Hong says the overall project needs to be considered from a more comprehensive perspective: Due to the criticality of the starting material, everything from cell sourcing, patient coordination and scheduling for collection/infusion, transportation logistics, and manufacturing logistics needs to be coordinated, ensuring the highest standards, regulatory compliance, and safety throughout the process.

To meet these needs, Lonza is building a network of partners to develop a fully integrated vein-to-vein solution, that is, a system that includes all touch points involved in patient scheduling and sample collection, through material shipping logistics, manufacturing, and eventually the infusion of the cell therapy back into the patient. The partner network, Hong indicates, will help participants define smart workflows and execute an integration strategy. Hong sums up the networks therapeutic implications as follows: We believe these partnerships will decrease time to clinical program setup.

Lonza has more than a 20-year history of providing clinical and commercial manufacturing. Hong asserts, Our company brings to the table our process development and manufacturing experience along with proprietary solutions including a manufacturing execution system solution, MODA-ESTM, for electronic batch records and manufacturing traceability. In addition, we have announced partnerships with Vineti for a supply chain orchestration system and Cryoport to aid in shipping and logistics.

Lonza is also looking beyond CAR T-cell therapies. We would not limit our solutions and partnerships to autologous cell therapies, Hong declares. We can envision solutions for our in vivo viral vector manufacturing clients as well as our traditional allogeneic cell therapy clients.

View post:
CAR T-Cell Optimization Starts in Production, Extends to Therapy - Genetic Engineering & Biotechnology News

Read More...

Genetic Engineering Market 2020 Share Growing Rapidly with Recent Trends, Revenue, Top Players and Forecast to 2027 – Scientect

Wednesday, September 2nd, 2020

Fort Collins, Colorado Reports Globe recently added the Genetic Engineering Market research report which has an in-depth scenario analysis of the market size, share, demand, growth, trends, and the forecast from 2020-2027. The report deals with the impact analysis of the COVID-19 pandemic. The COVID-19 pandemic has affected export-import, demand and industry trends and is expected to have economic effects on the market. The report provides a comprehensive analysis of the impact of the pandemic across the industry and an overview of a post-COVID-19 market scenario.

The report mainly mentions definitions, classifications, applications, and market reviews of the Genetic Engineering industry. It also includes product portfolios, manufacturing processes, cost analyzes, structures and the gross margin of the industry. It also offers a comprehensive analysis of key competitors, their regional breakdown and market size.

Global Genetic Engineering Market to reach USD XX billion by 2025.Global Genetic Engineering Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2019-2026.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The report provides a comprehensive analysis in an organized manner in the form of tables, graphs, charts, figures, and diagrams. The organized data paves the way for thorough examination and research of the current and future outlook of the market.

The examination of the Genetic Engineering industry provides an in-depth analysis of the key market drivers, opportunities, challenges, and their impact on the working of the market. The technological advancements and product developments, driving the demands of the market are also covered in the report.

The report provides comprehensive data on the Genetic Engineering market and its trends to assist the reader in formulating decisions to accelerate the business. The report provides a complete overview of the economic scenario of the market, along with benefits and limitations.

Genetic Engineering market report contains industrial chain analysis and value chain analysis to provide a comprehensive view of the Genetic Engineering market. The study is composed of market analysis along with a detailed analysis of the application segments, product types, market size, growth rate, and current and emerging trends in the industry.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

By Devices:

By Techniques:

By End-User:

By Application:

Geographically, the market is spread across several key geographical regions, and the report covers the regional analysis as well as the production, consumption, revenue, and market share in those regions for the forecast period of 2020-2027. The regions includeNorth America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa.

Radical Coverage of the Genetic Engineering Market:

Thank you for reading our report. For further queries on the report and customization, please connect with us. Our team will ensure you get the report best suited for your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View original post here:
Genetic Engineering Market 2020 Share Growing Rapidly with Recent Trends, Revenue, Top Players and Forecast to 2027 - Scientect

Read More...

From Cotton to Brinjal: Fraudulent GMO Project in India Sustained by Deception – CounterPunch

Wednesday, September 2nd, 2020

Insecticidal Bt (Bacillus thuringiensis) cotton is the first and only GM (genetically modified) crop that has been approved in India. It has been cultivated in the country for more than 20 years. In a formal statement to the Supreme Court of India, the Indian government has asserted that hybrid Bt cotton is an outstanding success. It therefore argues that Bt cotton is a templatefor the introduction of GM food crops.

However, over the last week, two important webinars took place that challenged the governments stance. The first was on Bt cotton and involved a panel of internationally renowned scientists who conclusively debunked the myth of Bt cotton success in India. The webinar, organised by the Centre for Sustainable Agriculture and Jatan, focused on an evidence-based evaluation of 18 years of approved Bt cotton cultivation in India.

The second webinar discussed the case of Bt brinjal, which the countrys apex regulatory body, the Genetic Engineering Appraisal Committee (GEAC), has brought to the brink of commercialisation. The webinar highlighted deep-seated problems with regulatory processes in India and outlined how the GEAC is dogged by secrecy, conflicts of interest and (scientific) fraud: participants outlined how the GEAC has been colluding with crop developers and seed companies to drive GM crops into agriculture.

Bt cotton failure

The panel for the Bt cotton webinar (YouTube: Bt Cotton in India: Myths & Realities An Evidence-Based Evaluation) on 24 August included Dr Andrew Paul Gutierrez, senior emeritus professor in the College of Natural Resources at the University of California at Berkeley; Dr Keshav Kranthi, former director of Central Institute for Cotton Research in India; Dr Peter Kenmore, former FAO representative in India, and Dr Hans Herren, World Food Prize Laureate.

Dr Herren said that the failure of Bt cotton is a classic representation of what an unsound science of plant protection and faulty direction of agricultural development can lead to.

He explained:

Bt hybrid technology in India represents an error-driven policy that has led to the denial and non-implementation of the real solutions for the revival of cotton in India, which lie in HDSS (high density short season) planting of non-Bt/GMO cotton in pure line varieties of native desi species and American cotton species.

He argued that a transformation of agriculture and the food system is required; one that entails a shift to agroecology, which includes regenerative, organic, biodynamic, permaculture and natural farming practices.

Dr Kenmore said that Bt cotton is an aging pest control technology:

It follows the same path worn down by generations of insecticide molecules from arsenic to DDT to BHC to endosulfan to monocrotophos to carbaryl to imidacloprid. In-house research aims for each molecule to be packaged biochemically, legally and commercially before it is released and promoted. Corporate and public policy actors then claim yield increases but deliver no more than temporary pest suppression, secondary pest release and pest resistance.

Recurrent cycles of crises have sparked public action and ecological field research which creates locally adapted agroecological strategies.

He added that this agroecology:

now gathers global support from citizens groups, governments and UN-FAO. Their robust local solutions in Indian cotton do not require any new molecules, including endo-toxins like in Bt cotton.

Prof Gutierrez presented the ecological reasons as to why hybrid Bt cotton failed in India: long season Bt cotton introduced in India was incorporated into hybrids that trapped farmers into biotech and insecticide treadmills that benefited GMO seed manufacturers.

He noted:

The cultivation of long-season hybrid Bt cotton in rainfed areas is unique to India. It is a value capture mechanism that does not contribute to yield, is a major contributor to low yield stagnation and contributes to increasing production costs.

Prof Gutierrez asserted that increases in cotton farmer suicides are related to the resulting economic distress.

He argued:

A viable solution to the current GM hybrid system is adoption of improved non-GM high-density short-season fertile cotton varieties.

Presenting data on yields, insecticide usage, irrigation, fertiliser usage and pest incidence and resistance, Dr Keshav Kranthi said that a critical analysis of official statistics (eands.dacnet.nic.inandcotcorp.gov.in) shows that Bt hybrid technology has not been providing any tangible benefits in India either in yield or insecticide usage.

He said that cotton yields are the lowest in the world in Maharashtra, despite being saturated with Bt hybrids and the highest use of fertilisers. Yields in Maharashtra are less than in rainfed Africa where there is hardly any usage of technologies such as Bt, hybrids, fertilisers, pesticides or irrigation.

It is revealing that Indian cotton yields rank 36th in the world and have been stagnant in the past 15 years and insecticide usage has been constantly increasing after 2005, despite an increase in area under Bt cotton.

Dr Kranthi argued that research also shows that the Bt hybrid technology has failed the test of sustainability with resistance in pink bollworm to Bt cotton, increasing sucking pest infestation, increasing trends in insecticide and fertiliser usage, increasing costs and negative net returns in 2014 and 2015.

Dr Herren said that GMOs exemplify the case of a technology searching for an application:

It is essentially about treating symptoms, rather than taking a systems approach to create resilient, productive and bio-diverse food systems in the widest sense and to provide sustainable and affordable solutions in its social, environmental and economic dimensions.

He went on to argue that the failure of Bt cotton is a classic representation of what an unsound science of plant protection and a faulty direction of agricultural development can lead to:

We need to push aside the vested interests blocking the transformation with the baseless arguments of the world needs more food and design and implement policies that are forward looking We have all the needed scientific and practical evidence that the agroecological approaches to food and nutrition security work successfully.

Bt brinjal the danger is back

The governments attempt to use a failed technology as a template for driving GMOs into agriculture has been exposed. Nevertheless, the GEAC has been moving forward with late-stage trials of Bt brinjal, while ignoring the issues and arguments against its commercialisation that were forwarded a decade ago.

In February 2010, the Indian government placed an indefinite moratorium on the release of Bt brinjal after numerous independent scientific experts from India and abroad had pointed out safety concerns based on data and reports in the biosafety dossier that Mahyco, the crop developer, had submitted to the regulators.

The then Minister of the Ministry of Environment and Forests Jairam Ramesh had instituted a unique four-month scientific enquiry and public hearings. His decision to reject the commercialisation of Bt brinjal was supported by advice from the renowned scientists.Their collective appraisals demonstrated serious environmental and biosafety concerns.

Jairam Ramesh pronounced a moratorium on Bt brinjal in February 2010 by stating:

it is my duty to adopt a cautious, precautionary principle-based approach and impose a moratorium on the release of Bt brinjal, till such time independent scientific studies establish, to the satisfaction of both the public and professionals, the safety of the product from the point of view of its long-term impact on human health and environment, including the rich genetic wealth existing in brinjal in our country.

The moratorium has not been lifted and the conditions he set out have still not been met. Moreover, five high-level reportshave advised against the adoption of GM crops in India. Appointed by the Supreme Court, the Technical Expert Committee (TEC) Final Report (2013) was scathing about the prevailing regulatory system and highlighted its inadequacies. The TEC went a step further by recommending a 10-year moratorium on the commercial release of all GM crops.

The regulatory process was shown to lack competency, possessed endemic conflicts of interest and demonstrated a lack of expertise in GMO risk assessment protocols, including food safety assessment and the assessment of environmental impacts.

Ten years on and regulators have done nothing to address this woeful state of affairs. As we have seen with the relentless push to get GM mustard commercialised, the problems persist. Through numerous submissions to the Supreme Court, Aruna Rodrigues has described how GM mustard is being forced through withflawed tests (or no tests) and a lack of public scrutiny.Regulators are seriously conflicted: they promote GMOs openly, fund them and then regulate them.

And this is precisely what the webinar Bt brinjal the danger is back (watch onYouTube) discussed on 27 August. Organised by the Coalition for a GM-Free India, the webinar was arranged because the regulators have again brought to the brink of commercialisation a new Bt brinjal event a different Bt brinjal than the 2010 version. Also included in the webinar were the experiences of Bt brinjal introduction in Bangladesh.

Dr Ramanjaneyulu (Centre for Sustainable Agriculture) highlighted how need has never been established for Bt brinjal of which India is a recognised centre of diversity. The argument for Bt brinjal in the run-up to Jairam Rameshs moratorium was that pesticide use is a problem in containing the brinjal fruit and shoot borer. He noted that Bt brinjal was promoted by Monsanto, USAID and Cornell University, but serious protocol violations, environmental contamination concerns and potential adverse health impacts were discovered.

He outlined simple non-pesticidal, agroecological management practises that can and are being used to deal with the brinjal fruit and shoot borer.

Farida Akhter of UBINIG (Policy Research for Development Alternative) outlined how the introduction of Bt brinjal in Bangladesh was not needed but imposed on the country, which has 248 varieties of brinjal. Where pesticide use is problematic, she argued that it concerns hybrid varieties rather than traditional cultivars of which 24 varieties are resistant to fruit and shoot borer.

Akhter said that poor quality brinjal and financial losses for farmers have been major issues. Many have abandoned Bt brinjal, but farmers have received incentives to cultivate and where they have done so, fertiliser use has increased and there have been many pest attacks, with 35 different types of pesticides applied.

The Bill Gates-funded Cornell Alliance for Science, a public relations entity that promotes GM agriculture, and USAID, which serves the interests of the GMO biotech sector, tried to sell Bt brinjal on the basis it would save people from the overuse of pesticides and related illnesses. But Akhter argued that Bangladesh was targeted because the Philippines and India had rejected Bt brinjal. Again, protocol violations occurred leading to its introduction and Akhter concluded that there was no scientific basis for Bt brinjal: its introduction was political.

As for India, event EE1, the initial Bt brinjal, has now been replaced by event 142, a different Bt brinjal. Kavitha Kuruganti (Alliance for Sustainable and Holistic Agriculture) explained this in the webinar and notes that the GEAC, immediately after the 2010 moratorium was announced, went straight ahead and sanctioned new trials for this Bt brinjal. The GEAC basically stated that the moratorium did not apply to this version, while ignoring all the criticisms about lack of competence, conflicts of interest, non-transparency and protocol violations. It was effectively business as usual!

With event EE1, Kuruganti implied that the GEAC acted more like a servant for Mayco and its Monsanto master. Nothing has changed. She noted the ongoing revolving door between crop developers (even patent holders) and regulators. As before, developers-cum-lobbyists were actually sitting on regulatory bodies as event 142 was proceeding.

Under public-private-partnership arrangements, event 142 has been licensed to private companies for biosafety testing/commercialisation. Despite major concerns, the GEAC has pressed ahead with various trials. In May 2020, under lockdown, Kuruganti notes that the GEAC held a virtual meeting and sanctioned what were effectively final trials prior to commercialisation. She explains that important information and vital data is not in the public domain.

According to Kuruganti, the regulator sits with the crop developer and the companies and grant biosafety clearance, claiming all tests (soil, pollen flow, toxicity, etc) are complete. What is also disturbing is that these licensed companies have closed and opened under new names (with the same people in charge), thereby making accountability and liability fixing very difficult if something were to go wrong further down the line.

She concludes that the story of event 142 is even worse than event EE1:

Once again, they are certainly hiding things that they dont want conscientious scientists and aware citizens to see and know.

Taken together, the two webinars highlighted how hybrid Bt cotton is being deceptively used as a template for rolling out GM food crops: a fraud being used to promote another fraud in order to force unnecessary GMOs into Indian agriculture.

See the original post:
From Cotton to Brinjal: Fraudulent GMO Project in India Sustained by Deception - CounterPunch

Read More...

Bacterial Superglue Allows Adhesion to the Gut – Genetic Engineering & Biotechnology News

Wednesday, September 2nd, 2020

Before bacteria colonize a tissue in the human body, such as the intestine, they have to attach. Not only that, they have to achieve firm adhesion under hydrodynamic flow. New research reports a molecular mechanism behind an ultrastable protein complex responsible for resisting shear forces and adhering bacteria to cellulose fibers in the human gut. The results explain how gut microbes regulate cell adhesion strength at high shear stress through intricate molecular mechanisms including dual-binding modes, mechanical allostery, and catch bonds.

The researchers used single-molecule force spectroscopy (SMFS), single-molecule FRET (smFRET), and molecular dynamics (MD) simulations to uncover that two different binding modes allow bacteria to withstand the shear forces in the body. The findings are published in Nature Communications in the paper titled, High force catch bond mechanism of bacterial adhesion in the human gut.

Cellulose is a major building block of plant cell walls, consisting of molecules linked together into solid fibers. For humans, cellulose is indigestible, and the majority of gut bacteria lack the enzymes required to break down cellulose.

However, recently genetic material from the cellulose-degrading bacterium R. champanellensis was detected in human gut samples. Bacterial colonization of the intestine is essential for human physiology, and understanding how gut bacteria adhere to cellulose broadens our knowledge of the microbiome and its relationship to human health.

The bacterium under investigation uses an intricate network of scaffold proteins and enzymes on the outer cell wall, referred to as a cellulosome network, to attach to and degrade cellulose fibers. These cellulosome networks are held together by families of interacting proteins.

Of particular interest is the cohesin-dockerin interaction responsible for anchoring the cellulosome network to the cell wall. This interaction needs to withstand shear forces in the body to adhere to fiber. This vital feature motivated the researchers to investigate in more detail how the anchoring complex responds to mechanical forces.

By using a combination of single-molecule atomic force microscopy, single-molecule fluorescence, and molecular dynamics simulations, Michael Nash, PhD, assistant professor with joint appointments at the University of Basel, department of chemistry, and at ETH Zurich, department of biosystems science & engineering, along with collaborators from LMU Munich and Auburn University, studied how the complex resists external force.

Two binding modes allow bacteria to stick to surfaces under shear flow

They were able to show that the complex exhibits a rare behavior called dual binding mode, where the proteins form a complex in two distinct ways. The researchers found that the two binding modes have very different mechanical properties, with one breaking at low forces of around 200 piconewtons and the other exhibiting a much higher stability breaking only at 600 piconewtons of force.

Further analysis showed that the protein complex displays a behavior called a catch bond, meaning that the protein interaction becomes stronger as force is ramped up. The dynamics of this interaction are believed to allow the bacteria to adhere to cellulose under shear stress and release the complex in response to new substrates or to explore new environments.

We clearly observe the dual binding modes, but can only speculate on their biological significance. We think the bacteria might control the binding mode preference by modifying the proteins. This would allow switching from a low to high adhesion state depending on the environment, Nash explained.

By shedding light on this natural adhesion mechanism, these findings set the stage for the development of artificial molecular mechanisms that exhibit similar behavior but bind to disease targets. Such materials could have applications in bio-based medical superglues or shear-enhanced binding of therapeutic nanoparticles inside the body. For now, we are excited to return to the laboratory and see what sticks, said Nash.

Read the original here:
Bacterial Superglue Allows Adhesion to the Gut - Genetic Engineering & Biotechnology News

Read More...

Nucleic Acid Isolation and Purification Market : The Rescuer in COVID-19 Crisis, Says TMR – Owned

Wednesday, September 2nd, 2020

Nucleic acid isolation and purification is an initial step in molecular biology studies and recombinant DNA techniques. The process of isolation includes mechanical and chemical disruption, enzymatic digestion, while the purification involves combination of extraction/precipitation, chromatography, centrifugation, electrophoresis, and affinity separation.

View Report : https://www.transparencymarketresearch.com/nucleic-acid-isolation-purification-market.html

This technique has wide applications in the field of genetic engineering, life science research, forensics and molecular diagnostics. Nucleic acid isolation helps in processing of more sample in less time, minimizes nucleic acid loss ad degradation and increases laboratory efficiency and effectiveness. The purified product can thus be used in recombinant technology methods, and be used in targeted purposes in research.

The rising demand of pure nucleic acids in pharmaceutical and biotechnological industries, and growing use of nucleic acid-based tests in diagnosis have propelled the growth of this market across the globe. Moreover, increasing applications of these techniques in various fields such as genetic engineering, life science research, forensics and molecular diagnostics and government funding in R&Ds and the recent technological innovations are expected to fuel the growth of this market.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9521

In addition, emergence of new technologies in molecular diagnostics, expression analysis and genotyping would create an opportunity for the suppliers in future. However, low market penetration of automated nucleic acid isolation and purification procedures in developing countries, is a key factor restraining the growth of global nucleic acid isolation and purification market. Similarly, higher prices of the instruments associated with these procedures is one of the major challenges for this market. New product development, mergers and acquisition and partnership are some of the key trends in nucleic acid isolation and purification market.

The market is segmented into technology, application, product, end user, and geography. Based on various type of technology, the market can be segmented as: columnbased, magnetic bead-based, reagent-based, and other (anion exchange-based, glass fiber-based) for DNA and RNA isolation and purification. Column-based technology for DNA isolation and purification commands the largest share of the global market. Magnetic bead-based technologyis poised to grow at fastest rate.

Request For Covid19 Impact Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=9521

Application segments of this market includes genomic DNA isolation and purification, micro RNA isolation and purification, blood DNA isolation and purification, mRNA isolation and purification, plasmid DNA isolation and purification, total RNA isolation and purification, and PCR clean up. The plasmid DNA isolation and purification is the leading market segment by application. The end-users of the market are academic research, hospitals and diagnostic centers, pharmaceutical and biotechnology companies, contract research organizations, and other end users. Nucleic acid isolation and purification market have its major share in academic research organizations.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

North America holds the leading position in the Nucleic Acid Isolation and Purification market followed by Europe. Asia Pacific is the most promising market for the growth of market due to various emerging economies. The market in the region is easy to penetrate and it is expected to have a huge future scope in the region, especially India and China, so the players are looking invest more in Asia-Pacific region. Some of the key players in global Nucleic Acid Isolation and Purification Market are Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Danaher Corporation (U.S.), Illumina Inc. (U.S.), Life Technologies (U.S.), Promega Corporation (U.S.)., among others.

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-radiation-therapy-market-to-reach-us-8-6-bn-by-2026product-approvals-to-drive-growth-transparency-market-research-300998453.html

2.https://www.biospace.com/article/dna-test-kits-market-increase-in-demand-for-ancestry-testing-to-drive-market/

See more here:
Nucleic Acid Isolation and Purification Market : The Rescuer in COVID-19 Crisis, Says TMR - Owned

Read More...

Eye health in a pandemic: Keeping vision safe with increased screen time – 13newsnow.com WVEC

Wednesday, September 2nd, 2020

We are in front of computer screens more than ever before. What does that mean with staying eye healthy?

August is Children's Eye Health and Safety Month, perfectly positioned for parents as a reminder to add a visit to the optometrist to your back-to-school checklist. Only this year, eye safety is more important than ever before.

Because of the COVID-19 pandemic, kids and adults alike are spending more time in front of a computer screen than ever before. Children are taking school classes at home virtually, while many parents are still working from home. That means increased screen time, and the potential for eye damage if you're not careful.

"Any time youre spending more than two hours continuously staring at a screen, we are worried about digital eyestrain and discomfort," said Dr. Katherine White is an optometrist with Kirn Family Eye Care in Susquehanna Township, Dauphin County.

Dr. White suggests good eye health starts with a comfortable workspace. A chair with good back support will help prevent neck strain. A flat surface slightly below eye level for a laptop or computer kept about an arm's reach away will prevent digital eye strain, and ultimately keep you from getting headaches.

White recommends everyone working from home subscribe to the '20-20-20 rule': That's every 20 minutes, you should look across the room, at least 20 feet away, for about 20 seconds. If you can get outside, Dr. White says simply taking a break away from your screen will help eye sight. If not, try to rest your eyes for 15 minutes every two hours with no other screens around.

For kids, it is recommended they stop using electronics at least an hour before bed time. Doctor White says studies have shown the more screen time closer to bed, the tougher it is to fall asleep.

Symptoms such as dry eyes, irritation or burning, or headaches should be responded with a call to an optometrist and a visit to the eye doctor.

More here:
Eye health in a pandemic: Keeping vision safe with increased screen time - 13newsnow.com WVEC

Read More...

Guess What’s Under the Hood of the Subaru Levorg? ADAS and Programmable Logic – Embedded Computing Design

Wednesday, September 2nd, 2020

The Subaru 2020 Levorg mid-size touring wagon was made available for pre-order last month and introduced a range of features such as a new 1.8-liter, four-cylinder engine and continuously variable automatic transmission (CVT). But perhaps the most exciting feature is on the safety front, as the car is the first in the Subaru fleet to contain the companys next-generation EyeSight ADAS technology.

The EyeSight stereo-based vision system assists with passenger safety with three key feature sets. Adaptive cruise control (ACC) optimizes vehicle speed during highway driving; lane keep assist (LKA) helps prevent cars from swerving out of their lane; and auto de-acceleration, pre-collision braking, and hands-off driving functionality monitor surrounding traffic and provide mechanisms for avoiding unintended acceleration, head-on collisions, and other serious accidents (Figure 1).

Figure 1. The EyeSight platform consists of two stereo cameras and accepts inputs from four radars positioned around the vehicle.

The EyeSight platform consists of two color stereo cameras mounted on the inside of the Levorgs windshield near the cars rearview mirror. The cameras, as well as four external radars, capture images of cars, pedestrians, lane dividers, traffic, etc., which the system then analyzes and, if needed, sends signals to various control systems like steering or brakes to take corrective action (Figure 2). These actions could include accelerating, decelerating, changing direction, flashing lights, honking, and other methods of alerting drivers of possible danger.

Figure 2. Subarus EyeSight Advanced Driver Assistance System (ADAS) uses stereo vision to help motorists avoid collisions, pedestrians, and other road hazards.

By being able to monitor traffic and take action in dangerous driving situations, the next-generation ADAS subsystem is essentially an extra pair of eyes on the road.

In developing its latest stereo vision-based ADAS technology, Subaru enlisted programmable processing vendor, Xilinx. The main compute engine on the Eyesight system is an ASIL-rated, 16 nm Zynq UltraScale+ multi-processor system-on-a-chip (MPSoC), which integrates a 64-bit Arm Cortex-A53 core, two Arm Cortex-R5 real-time cores, and programmable logic that provides hardware flexibility for a range of functions (Figure 3).

Figure 3. The Subaru EyeSight ADAS system is based on a Xilinx Zynq UltraScale+ MPSoC with multiple Arm cores and programmable logic fabric.

In the EyeSight system, the Zynq UltraScale+ MPSoC fuses data from four radar sensors on the Levorg; performs image detection, classification, and perception operations; and delivers that information to the Levorg braking system. The MPSoCs 16 nm process technology provides the performance needed for stereo processing of radar data and the conversion of that data into 3D point clouds (Figure 3).

Figure 3. The MPSoC in the EyeSight ADAS system process radar data and convert them into point clouds so that object detection algorithms can be applied.

The Zynq UltraScale+ MPSoCs Cortex-A53 subsystem handles real-time video, graphics, waveform, and packet processing, while the R5 cores and video codec unit (VCU) execute motor control, sensor fusion, wireless communication, and other multimedia tasks. Available as an automotive-grade platform with multiple power domains, the MPSoC delivers exceptional performance per watt operation as well as functional safety and security features.

Unlike common approaches, the image processing technology adopted in our new generation system scans everything captured by stereo cameras and creates high-precision 3D point clouds, enabling us to offer advanced features such as pre-collision braking at an intersection and assisting with hands-off driving in traffic congestion on a highway, says Tetsuo Fujinuki, CTO at Subaru. Because Xilinx automotive devices contain built-in capabilities that allow us to meet strict ASIL requirements, they are unquestionably the best technology to implement Subarus new ADAS vision system.

Subarus Eyesight technology received the highest IIHS rating in 2019-20, and is designed to provide drivers with safe and tested technology that can accurately react to driving scenarios. Of course, none of this is possible without advanced computational capabilities afforded by the automotive-grade Zynq UltraScale+ MPSoC.

The MPSoC is doing all of the detection, classification, and perception on the EyeSight, and providing input to the braking system. Its also doing sensor fusion of the radar inputs, says Willard Tu, Senior Director of Automotive at Xilinx. Everybody realizes that the more sensors you put on cars, the richer the fusion of data you get.

This is a super opportunity for programmable logic, he adds.

For more information, visit Xilinx website.

Tiera Oliver, edtorial intern for Embedded Computing Design, is responsible for web content edits as well as newsletter updates. She also assists in news content as far as constructing and editing stories. Before interning for ECD, Tiera had recently graduated from Northern Arizona University where she received her B.A. in journalism and political science and worked as a news reporter for the university's student led newspaper, The Lumberjack.

Read more from the original source:
Guess What's Under the Hood of the Subaru Levorg? ADAS and Programmable Logic - Embedded Computing Design

Read More...

Vision Care Market Covid-19 Scenario, Growth Opportunities, And Forecast 2027 | Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor – Scientect

Wednesday, September 2nd, 2020

Vision Care Market analysis on the global market is an in-depth study that provides an arrangement of efficient market authenticities. The study shows statistics on the market status of the leading market players and offers key trends and opportunities in the market. The analysis of the global market begins with an industry-based framework and outlines the current information of the global market, complemented by current status records.

Vision care is the care and treatment of eyes, eyesight conditions, and vision. The exploding use of electronic devices for everyday functioning has also been related to eye disorders. In recent years, the use of technology has particularly increased among children. Studies suggest excessive use of electronic devices could lead to eye disorders. This indirectly is stoking demand for vision care products.

Ask for Sample Copy of This Report: https://www.theinsightpartners.com/sample/TIPRE00011953/

Top Key Players Profiled in This Report:

Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor, Johnson & Johnson, LUXOTTICA GROUP, Rodenstock, Safilo Group, ZEISS

The key questions answered in the report:

The vision care market is driving due to the rising geriatric population more susceptible to eye diseases and technological advances in eye care devices. Moreover, the raise awareness for eye health and to address vision-related problems is also serving to boost the vision care market.

Get Discount on This Report: https://www.theinsightpartners.com/discount/TIPRE00011953/

This research report represents a comprehensive overview of the competitive landscape of the Vision Care Market. Furthermore, it offers massive data relating to the recent trends, technological advancements, facts and figures, and methodologies. The research report analyzes the global market in a detailed and concise manner for better insights into the businesses.

Research studies have taken the help of graphical presentation techniques such as information graphics, charts, tables and diagrams. This Vision Care provides guidelines for both established players and new entrants in the market.

A detailed expansion of the Global Vision Care Market has been provided by applying industry analysis techniques such as SWOT analysis. Collectively, this research report provides a reliable assessment of the global market to present the overall structure of the businesses.

Interested in Purchasing this Report Click @ https://www.theinsightpartners.com/buy/TIPRE00011953/

Some Points of Table of Contents:

Chapter 1. Introduction

Chapter 2. Vision Care Market Key Takeaways

Chapter 3. Research Methodology

Chapter 4. Global Vision Care Market Market Landscape

Chapter 5. Global Vision Care market Key Market Dynamics

Chapter 6. Vision Care Market Global Analysis

Chapter 7 to 9. Detail Market Segmentation

Chapter 10. Impact Of COVID-19 Pandemic On Global Rare Neurological Diseases Treatment Market

Chapter 11. Vision Care Market Industry Landscape

Chapter 12. Company Profiles

Chapter 13. Appendix

About Us:

The Insight Partners offer our clients an opportunity to customize our off the shelf syndicated reports at no additional cost. This provides our clients with precise intelligence they require in turn saving them thousands of dollars in commissioning large consulting studies. The Insight Partners specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact:

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email ID: [emailprotected]

Website: http://www.theinsightpartners.com

Read the rest here:
Vision Care Market Covid-19 Scenario, Growth Opportunities, And Forecast 2027 | Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor - Scientect

Read More...

Cat who lost eye to cancer finds forever home with partially sighted owner in Leeds – Yorkshire Evening Post

Wednesday, September 2nd, 2020

11-year-old George has found a new family.

11-year-old George was rescued when he was a young stray.

Sadly, his owner died and he was taken to Cats Protection on Gildersome Lane in Morley.

While there he had a routine vet appointment where they found cancer in his eye.

Unfortunately, his eye had to be removed.

Luckily, George has now found his forever home.

He has been adopted by Kate, from Gildersome, who is partially sighted due to her Usher syndrome diagnosis.

Usher syndrome is a degenerative condition that causes hearing and vision loss.

Kate said: I saw George on the Cats Protection website and, having begun to lose part of my sight in the past few years, I immediately fell in love with this gorgeous chap.

Having only one eye certainly hasnt held him back.

He loves joining us for story time with my five-year-old daughter, and, while he prefers to stay close to home, hes been out walking along fences and climbing trees.

Due to coronavirus restrictions, Kate could not visit George before he was adopted, instead getting to know him through videos.

She said: George was delivered directly to our door and he settled in straight away, following us around and giving us cuddles."

Cats Protection rehoming and welfare assistant Diane Armer said: George was particularly popular with everyone at the centre, he has such a fantastic personality.

It is so lovely to hear that George has settled in so well.

A message from the Editor: Leeds has a fantastic story to tell - and the Yorkshire Evening Post has been rooted firmly at the heart of telling the stories of our city since 1890. We believe in ourselves and hope you believe in us too. We need your support to help ensure we can continue to be at the heart of life in Leeds. Subscribe to our website and enjoy unlimited access to local news and information online and on our app. With a digital subscription, you can read more than 5 articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Click here to subscribe. For more details on our newspaper subscription offers click here.

Here is the original post:
Cat who lost eye to cancer finds forever home with partially sighted owner in Leeds - Yorkshire Evening Post

Read More...

Page 42«..1020..41424344


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick